Drugs / Q10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00113477 | May 2005 → Dec 2007 | statin toxicity | Oslo University Hospital | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05941910 Comparator | Apr → Aug 2023 | NAFLD1 | Attikon Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02796378 Comparator | Jun 2016 → Jul 2021 | cardiovascular disorder, diabetes mellitus | University of Copenhagen | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Laboratorios Rubió | Results OTC Supplements: 2025’s Revolution in Preventive Health laboratoriosrubio.com ↗
For heart failure patients, a landmark Q-SYMBIO trial showed that 300mg daily CoQ10 supplementation reduced major cardiovascular events and mortality by roughly 50%. |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Q10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02796378 ↗ |
| Known as | coenzyme Q10 | “effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD” NCT05941910 ↗ |
| Known as | CoQ10 | “effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD” NCT05941910 ↗ |
| Route | Oral | “400 mg of oral supplementation with Q10” NCT02796378 ↗ |